ITERUM THERAPEUTICS PLC (ITRM) Stock Price, Quote, News and Overview
NASDAQ:ITRM - Nasdaq - IE000TTOOBX0 - Common Stock - Currency: USD
ITRM Quote, Performance and Key Statistics
1.1
+0.02 (+1.85%)
The current stock price of ITRM is 1.1 USD. In the past month the price decreased by -5.98%. In the past year, price decreased by -29.03%.
ITRM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 59.86 | 780.78B | ||
| JNJ | JOHNSON & JOHNSON | 15.53 | 376.23B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.01 | 307.32B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.75 | 225.73B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.47 | 224.59B | ||
| MRK | MERCK & CO. INC. | 10.68 | 209.31B | ||
| PFE | PFIZER INC | 7.54 | 137.25B | ||
| SNY | SANOFI-ADR | 14.36 | 135.72B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.89 | 102.91B | ||
| GSK | GSK PLC-SPON ADR | 7.09 | 79.05B | ||
| ZTS | ZOETIS INC | 26.59 | 70.23B | ||
| HLN | HALEON PLC-ADR | 21.84 | 48.28B |
Related stock screener links
About ITRM
Company Profile
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company is headquartered in Dublin, Dublin and currently employs 9 full-time employees. The company went IPO on 2018-05-25. The firm develops differentiated anti-infectives. The company offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The firm operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Company Info
ITERUM THERAPEUTICS PLC
3 Dublin Landings, North Wall Quay
DUBLIN DUBLIN 2 IE
CEO: Corey N. Fishman
Employees: 14
Company Website: https://www.iterumtx.com/
Investor Relations: http://ir.iterumtx.com
Phone: 8722256077
ITERUM THERAPEUTICS PLC / ITRM FAQ
What is the stock price of ITERUM THERAPEUTICS PLC today?
The current stock price of ITRM is 1.1 USD. The price increased by 1.85% in the last trading session.
What is the ticker symbol for ITERUM THERAPEUTICS PLC stock?
The exchange symbol of ITERUM THERAPEUTICS PLC is ITRM and it is listed on the Nasdaq exchange.
On which exchange is ITRM stock listed?
ITRM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ITERUM THERAPEUTICS PLC stock?
8 analysts have analysed ITRM and the average price target is 5.1 USD. This implies a price increase of 363.64% is expected in the next year compared to the current price of 1.1. Check the ITERUM THERAPEUTICS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ITERUM THERAPEUTICS PLC worth?
ITERUM THERAPEUTICS PLC (ITRM) has a market capitalization of 38.04M USD. This makes ITRM a Nano Cap stock.
How many employees does ITERUM THERAPEUTICS PLC have?
ITERUM THERAPEUTICS PLC (ITRM) currently has 14 employees.
What are the support and resistance levels for ITERUM THERAPEUTICS PLC (ITRM) stock?
ITERUM THERAPEUTICS PLC (ITRM) has a support level at 1.08 and a resistance level at 1.26. Check the full technical report for a detailed analysis of ITRM support and resistance levels.
Should I buy ITERUM THERAPEUTICS PLC (ITRM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ITRM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ITRM, evaluating the profitability, health, valuation and growth aspects
- ITERUM THERAPEUTICS PLC (ITRM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ITERUM THERAPEUTICS PLC (ITRM) Sales and EPS estimates to see what analysts future expectations are.
- ITERUM THERAPEUTICS PLC (ITRM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ITERUM THERAPEUTICS PLC (ITRM) Insider and Institutional Ownership to learn about the owners and their transactions.
- ITERUM THERAPEUTICS PLC (ITRM) Stock Chart to make your own analysis
- ITERUM THERAPEUTICS PLC (ITRM) Latest news and press-releases to stay up to date.
Does ITERUM THERAPEUTICS PLC (ITRM) stock pay dividends?
ITRM does not pay a dividend.
When does ITERUM THERAPEUTICS PLC (ITRM) report earnings?
ITERUM THERAPEUTICS PLC (ITRM) will report earnings on 2025-05-09.
What is the Price/Earnings (PE) ratio of ITERUM THERAPEUTICS PLC (ITRM)?
ITERUM THERAPEUTICS PLC (ITRM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.29).
What is the Short Interest ratio of ITERUM THERAPEUTICS PLC (ITRM) stock?
The outstanding short interest for ITERUM THERAPEUTICS PLC (ITRM) is 3.63% of its float. Check the ownership tab for more information on the ITRM short interest.
ITRM Technical Analysis
ITRM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ITRM. ITRM may be in some trouble as it scores bad on both profitability and health.
ITRM Financial Highlights
Over the last trailing twelve months ITRM reported a non-GAAP Earnings per Share(EPS) of -1.29. The EPS increased by 55.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.55% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ITRM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ITRM. The Buy consensus is the average rating of analysts ratings from 8 analysts.